Lymph node metastasis is one of the prognostic factors in gastric cancer. We have previously reported that decreased intercellular adhesion molecule-1 (ICAM-1) expression on cancer cells is associated with lymph node metastasis using a gastric cancer cell. In this study, we transfected ICAM-1 gene into a gastric cancer cell line, 2MLN, and analyzed the effect on lymph node metastasis in vitro and in vivo. 
However, gastric cancer is still the leading cause of death in Japan, and about 50 000 cancer-related deaths are reported annually. Metastases, such as lymph node metastasis, peritoneal metastasis and liver metastasis, are a common cause of death from gastric cancer. It has been reported that lymphatic involvement and lymph node metastasis are significantly related to the high rate of cancer death. 1, [3] [4] [5] Therefore, it is important to understand how to control lymph node metastasis in patients with gastric cancer by clarifying the mechanisms responsible for such metastasis.
Metastasis occurs subsequent to a sequential multistep process. 6) Previous studies of metastases have concentrated on invasion and adhesion ability of cancer cells. [7] [8] [9] [10] [11] Immune responses to cancer cells as well as the properties of cancer cells themselves might be responsible for metastases. However, few reports have discussed metastasis in terms of the immunological tolerance of cancer cells. Rejection of tumors is primarily mediated by cytotoxic lymphocytes (CTLs) and natural killer (NK) cells. 12, 13) These immune effector cells recognize cancer cells in two different ways, i.e., in a non-specific, nonmajor histocompatibility complex (MHC)-restricted manner and in an antigen-specific MHC-restricted manner. In non-MHC restricted recognition, intercellular adhesion molecule-1 (ICAM-1)/leukocyte function-associated antigen-1 (LFA-1) interaction plays an important role in adhesion to the target cells, which are lysed by NK cells and lymphocyte activated killer (LAK) cells. 14) In MHCrestricted recognition, not only the interaction of T-cell receptors with antigen/MHC molecule complex, but also additional second signal transmission through co-stimulatory molecules is required for optimal T-cell activation. [15] [16] [17] [18] ICAM-1 is one of the co-stimulatory molecules; ICAM-1 thus plays an important role in both types of recognition. The decrease or loss of co-stimulatory molecules might help cancer cells to escape from the immunosurveillance system, thereby contributing to progression and metastasis. [19] [20] [21] We have immunohistologically investigated the correlation between the expression of ICAM-1 on cancer cells and clinicopathological factors of 274 patients with invasive breast cancer, and revealed that ICAM-1 expression was significantly decreased in the cases with lymph node metastasis. 22) We have also revealed that decreased ICAM-1 expression on cancer cells is associated with lymph node metastasis using a gastric cancer cell line in an experimental model with mice. 23) These findings suggest that ICAM-1 plays an important role in the process of lymph node metastasis as a signal transmitter of MHC and non-MHC-restricted immune response.
In the last decade, there have been numerous studies of gene therapy for cancer; a variety of genes have been transduced. Most of these studies aimed at inhibiting tumor growth by transducing tumor suppressor genes such as p53. However, there have been few reports concerning gene therapy for cancer metastasis based on the metastatic mechanisms, especially for lymph node metastasis. In this study, we investigated the inhibitory effect on lymph node metastasis of the transduction of ICAM-1 into gastric cancer cells in vitro and in vivo.
MATERIALS AND METHODS
Mice Specific, pathogen-free, athymic BALB/c-nu/nu nude mice were purchased from Oriental Kobo (Tokyo). The mice were maintained under specific pathogen-free conditions and given sterile food and water ad libitum. Four-to six-week-old mice were used for the experiments. Cells and culture conditions The human gastric cancer cell line, OCUM-2M LN (2MLN), was used in this study. 2MLN cells have high lymph node metastatic potential, as previously reported. 23) Cells were cultivated in medium (see below) in 100 mm culture dishes (Falcon, Lincoln Park, NJ), and incubated at 37°C in a humidified atmosphere of 5% CO 2 in air. The culture medium was composed of Dulbecco's modified Eagle's medium (DMEM; Bioproducts, Walkersville, MD) with 10% fetal bovine serum (FBS; GIBCO/BRL, Grand Island, NY), 100 IU/ml of penicillin (ICN Biomedicals, Costa Mesa, CA), 100 µg/ ml of streptomycin penicillin (ICN Biomedicals), and 0.5 mM sodium pyruvate (Bioproducts). ICAM-1 transfection and selection of clones Transfection was carried out by lipofection, according to the manufacturer's instructions. In brief, 1×10 5 2MLN cells were seeded in 2 ml of complete medium. After incubation and until the cells were 50% confluent, transfection was performed, under the conditions described above. One microgram of pICAM-1, a full-length ICAM-1 cDNA inserted in the CDM8 expression vector (generously provided by Dr. Timothy Springer, Center for Blood Research, Inc., Harvard Medical School, Boston, MA) and 0.1 µg of pCMV-Script mammalian expression vector, containing the neomycin-and kanamycin-resistance gene, (Stratagene) were mixed with 3 µg of 2 mg/ml LIPO-FECTAMINE (GIBCO/BRL) in serum-free medium, and incubated at room temperature for 45 min to form DNAliposome complexes. Fifty percent confluent cells on a 35 mm tissue culture plate were washed twice with serumfree medium and 1 ml of the DNA-liposome complex was added. The cells were incubated for 5 h at 37°C in a CO 2 incubator and then 1 ml of DMEM with 20% FBS was added. After incubation for 18 h at 37°C, the medium was replaced with 10 ml of fresh complete medium. To select the transfected cells, cells were passaged 1:10 at 72 h after transfection into the selection medium containing 500 µg/ ml of "GENETICIN" (GIBCO/BRL), and expanded for 2 weeks. From these populations, many clones were obtained by the limiting dilution method. ICAM-1 expression was confirmed by FACScan Calibur (Becton Dickinson, San Jose, CA). A high-expressing clone was selected for this study, and was designated 2MLN/ICAM. 2MLN cells transduced with pCMV-expression vector only, designated as 2MLN/Vector, were used as the control cell line. 
Isolation of the peripheral blood mononuclear cells (PBMC)
Human PBMC were obtained from healthy volunteers using Mono-Poly Resolving Medium (Dainippon Pharmaceutical Co., Ltd., Tokyo) according to the manufacturer's instructions. Briefly, 7 ml of fresh anti-coagulated blood was laid gently onto 6 ml of the Resolving Medium in a 15 ml tube. The tube was centrifuged at 400g at room temperature for 40 min. After drawing off the plasma, the upper fraction containing mononuclear lymphocytes was transferred to a clean tube, and was washed with phosphate-buffered saline (PBS). The tube was centrifuged at 250g for 12 min, and the pellet was resuspended to a concentration of 5×10 6 /ml in DMEM with 10% FBS. Adhesion assay The in vitro adhesiveness of PBMC to cancer cells was assessed as previously described, with some modification. 24, 25) Briefly, cancer cells were plated onto 0.01% Poly Lysine (Sigma Chemical Co., St. Louis, MO)-precoated 96-well plates (Costar Co., Cambridge, MA) and cultured until confluent. The 96-well plates were placed on ice before addition of the PBMC. The PBMC (2×10 5 ) were added to each well in a final volume of 200 µl. The plates were placed on ice for 30 min, which allowed the PBMC to sink to the bottom. Then the plates were rapidly warmed to 37°C and incubated for 30 min or for 60 min. Non-adherent cells were washed with PBS. Cellular adhesion was quantified by 3-(4,5-dimethyl-2-thiazol)-2H tetrazolium bromide (MTT; Wako Pure Chemical Industries, Ltd., Tokyo) colorimetric assay, which is designed to measure the formazan product of MTT, using an MTP-120 microplate reader (Corona Electric Co., Ibaraki) to measure absorbance at 550 nm. The percentage of adhering PBMC with respect to all PBMC (% adhesion) was calculated as follows: % adhesion=(A−B)/T×100, where A=absorbance of experimental wells and B= absorbance of cancer cell wells, and T=absorbance of total PBMC added to each well. In vitro cytotoxicity assay We investigated the non-MHC restricted cytotoxicity by PBMC. Target cancer cells and PBMC were placed into a 96-well plate at an effector to target (E/T) ratio of 5, 10 and 20. Cells were incubated for 12 h at 37°C. For analysis of cytotoxicity, the Cyto Tox 96 assay (Promega, Madison, WI) was used, which quantitatively measures lactate dehydrogenase released upon cell lysis. Absorbance data at 490 nm were obtained using the MTP-120 microplate reader. The percentage of cancer cell lysis was calculated as follows: % cytotoxicity=(A−B− C)/(D−E)×100, where A=experimental lysis, B=effector spontaneous lysis, C=target spontaneous lysis, D=target maximum lysis, and E=target spontaneous lysis. Tumor growth of xenograft 2MLN/Vector cells or 2MLN/ICAM cells (5×10 6 ) in 200 µl of DMEM were inoculated subcutaneously into each nude mouse's lateral abdominal wall. Tumor areas were measured with a caliper every 2 days. Tumor growth following treatment with anti-asialo G M1 antibody Nude mice were treated by intraperitoneal injection of 40 µl/mouse of anti-asialo G M1 Ab on days −2, 0, 2, 4, 7, 10, and then every 3 days during observation. 2MLN/ICAM cells were inoculated into the subcutis of nude mice on day 0. This protocol is effective in depleting NK cells in mice. 26) Lymph node metastatic ability following orthotopic implantation of gastric cancer cells in vivo Each mouse was anesthetized with diethyl ether (Wako Pure Chemical Industries, Ltd.) and placed in the supine position. An upper-midline incision was made and the stomach was exposed. Using a 30-gauge needle, tumor cell suspensions (1×10 7 cells in 20 µl of DMEM) were inoculated into the middle of the greater curve of the glandular stomach. The stomach was then returned into the peritoneal cavity, and the abdominal wall was closed. The mice were killed 4 weeks after the implantation, and metastatic lymph nodes were excised and weighed. Primary tumors and metastatic lymph nodes were fixed in 10% formalin neutral buffer solution (Wako Pure Chemical Industries, Ltd.) and were stained with hematoxylin and eosin (H & E). Statistical analysis Differences between the control and experimental groups were analyzed using Student's t test. A P-value of less than 0.05 was considered statistically significant. (Fig. 2) . Enhanced ICAM-1 expression on 2MLN/ICAM cells increases the adhesiveness of PBMC to 2MLN/ICAM cells We investigated the effect of enhanced ICAM-1 expression on adhesiveness of PBMC to cancer cells. Fig.  3 shows the results of the adhesion assay. PBMC hardly adhered to 2MLN/Vector cells at any time point, whereas significantly larger numbers of PBMC adhered to 2MLN/ ICAM cells at 30, 60 and 90 min later, at 31%, 82% and 78%, respectively. PBMC show significantly increased lysis of 2MLN/ ICAM cells Next, we investigated the effect on PBMC cytotoxicity. The results are shown in Fig. 4 . The data reveal that 2MLN/ICAM cells were lysed to a significantly greater degree than 2MLN cells at each E/T ratio of 5-20. The primary purpose of this study was to clarify whether or not the decreased ICAM-1 expression on cancer cells is responsible for the escape of such cells from the immunosurveillance system; cancer cells would then be free to metastasize to the lymph nodes. In order to perform this investigation, we used a spontaneous lymph node metastatic model with orthotopic implantation. The results are shown in Table I . Tumorigenesis in the stomach was recognized in all inoculated mice. Lymph node metastasis by 2MLN cells and 2MLN/Vector cells was recognized in all inoculated mice, whereas 2MLN/ICAM cells induced lymph node metastasis in 6 of 7 inoculated mice. As shown in the photograph in Fig. 6A , lymph node metastases caused by 2MLN cells were recognized at the greater omentum as a large, protuberant and irregularly shaped nodule. In addition, several metastatic nodules were recognized at the hylus of the spleen, the lesser omentum, or the mesenterium. The primary lesion was concealed by these nodules. Metastases caused by 2MLN/Vector cells as well as 2MLN cells were found at distant lymph nodes. In contrast, lymph node metastases caused by 2MLN/ICAM cells were recognized as being fewer in number and smaller; metastasis was confined to the lesser omentum (Fig. 6B) (Table I) .
RESULTS

ICAM
Histological sections of primary tumors and metastatic lymph nodes are shown in Fig. 7 . The orthotopically implanted tumors in the stomach showed diffuse infiltration of cancer cells with abundant fibrous stroma. Only a few leukocytes were present in the 2MLN tumors with necrotic lesions (Fig. 7A) , whereas heavy infiltration of (Fig. 7B) . The infiltrating leukocytes were mononuclear. Metastatic lymph nodes associated with 2MLN cells were occupied with cancer cells, and few leukocytes were observed (Fig. 7C) . In the case of 2MLN/ICAM cells, many leukocytes were recognized, gathering around cancer cells (Fig. 7D) .
DISCUSSION
It has been reported that decreased ICAM-1 expression on cancer cells is closely associated with increased lymph node metastasis. [19] [20] [21] In this study, we transfected ICAM-1 genes into 2MLN cells to analyze the usefulness of gene therapy for lymph node metastasis of gastric cancer. A FACS analysis revealed that the transfected 2MLN/ICAM cells had expressed a greater amount of ICAM-1 molecules; the positive ratio of ICAM-1-expressing cells was increased. Using an ICAM-1 transfected cell line, 2MLN/ ICAM, we investigated the effect on immunogenicity and metastatic potential of ICAM-1 transduction.
An adhesion assay showed that a significantly greater amount of PBMC adhered to 2MLN/ICAM cells than to 2MLN/Vector cells. These findings indicate that ICAM-1 plays an important role in adhesion between cancer cells and PBMC. The lysis of 2MLN/ICAM cells by PBMC was significantly increased compared with that of 2MLN cells. Increased adhesion might allow PBMC more opportunity to lyse target cancer cells. These findings indicate that the transduction of ICAM-1 into cancer cells could be effective for inducing an enhanced immune response. The ICAM-1/LFA-1 interaction has been reported to participate in non-MHC restricted cytotoxicity mediated by NK cells 27, 28) and monocytes. 29) This interaction has also been reported to serve as a co-stimulus in the activation of CTLs by adhesion and also by signal transduction.
30) The effect of increased ICAM-1 expression could be amplified by not only MHC-restricted immune cells, but also by non-MHC-restricted immune cells.
The tumor growth of xenografted 2MLN/ICAM cells in vivo was significantly reduced compared with that of 2MLN/Vector cells. No difference in the in vitro growth rate was found between 2MLN/Vector cells and 2MLN/ ICAM cells, which indicates that the reduction of the tumor growth rate is not a direct result of the transfection process. The lower growth of 2MLN/ICAM cells in vivo was diminished by pretreatment of mice with anti-asialo G M1 Ab, which eliminates NK activity. These findings indicate that the regression of tumors is partly mediated by NK cells, and that ICAM-1 plays an important role in cytolysis by NK cells. It has been reported that human ICAM-1 has a 53% structural homology with murine ICAM-1. 31) There has been a report on the therapeutic efficacy of increasing ICAM-1 expression on sarcoma cells by transfecting human ICAM-1 gene using a murine model. 32) This paper and our result may suggest that human ICAM-1 can bind to murine LFA-1.
Lymph node metastatic ability of 2MLN/ICAM cells was significantly decreased compared with that of 2MLN cells and 2MLN/Vector cells in an orthotopic implantation model. Our model exhibited spontaneous lymph node metastasis and should thus be a useful model for analyzing the efficacy of various therapies for lymph node metastasis. The number of metastatic lymph nodes associated with 2MLN/ICAM cells was low or zero, and these metastases were only recognized in nearby regional lymph nodes, whereas 2MLN/Vector cells metastasized to several distant lymph nodes, like 2MLN cells. The total weight of metastatic nodes associated with 2MLN/ICAM cells was significantly less than that of metastatic nodes associated with 2MLN/Vector cells. Histological findings showed many infiltrating leukocytes in both 2MLN/ICAM tumors and metastatic lesions, whereas only a few leukocytes in the lesions associated with 2MLN cells. The above findings indicate that the loss or decrease of ICAM-1 expression on cancer cells is responsible for cancer cells' escaping from immunosurveillance. These findings might explain the mechanism of the relationship between decreased ICAM-1 expression on cancer cells and increased lymph node metastasis. The growth of xenografted tumor of 2MLN/ICAM was significantly reduced, which might be one of the reasons for the reduction of lymph node metastasis. However, histologic findings show that many more leukocytes were infiltrating metastatic lesions of 2MLN/ICAM cells than those of 2MLN/ Vector cells, as well as primary lesions, which could also be one of the reasons for the reduction of lymph node metastasis, and suggests that enhancing ICAM-1 expression inhibits the process of lymph node metastasis. In view of the fact that lymph node metastasis could be inhibited by enhancing ICAM-1 expression on cancer cells, ICAM-1 gene transduction could prove to be an effective gene therapy for metastasis of gastric cancer. Moreover, this would also be the case for other types of cancer which have frequent lymph node metastasis, such as breast or colon cancer, and have the same relationship between ICAM-1 expression on cancer cells and lymph node metastasis. 21, 22) Therefore, ICAM-1 gene transduction could also be a useful gene therapy in cases of lymph node metastasis associated with those types of cancers.
